- Home
- TDF vs TVRD Comparison
TDF vs TVRD Comparison
Compare TDF & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDF
- TVRD
- Stock Information
- Founded
- TDF 1994
- TVRD 2017
- Country
- TDF Singapore
- TVRD United States
- Employees
- TDF N/A
- TVRD N/A
- Industry
- TDF Finance/Investors Services
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- TDF Finance
- TVRD Health Care
- Exchange
- TDF Nasdaq
- TVRD Nasdaq
- Market Cap
- TDF 244.7M
- TVRD 246.5M
- IPO Year
- TDF N/A
- TVRD N/A
- Fundamental
- Price
- TDF $11.01
- TVRD $27.84
- Analyst Decision
- TDF
- TVRD Strong Buy
- Analyst Count
- TDF 0
- TVRD 5
- Target Price
- TDF N/A
- TVRD $59.20
- AVG Volume (30 Days)
- TDF 79.2K
- TVRD 21.8K
- Earning Date
- TDF 01-01-0001
- TVRD 08-14-2025
- Dividend Yield
- TDF N/A
- TVRD N/A
- EPS Growth
- TDF N/A
- TVRD N/A
- EPS
- TDF N/A
- TVRD N/A
- Revenue
- TDF N/A
- TVRD N/A
- Revenue This Year
- TDF N/A
- TVRD N/A
- Revenue Next Year
- TDF N/A
- TVRD N/A
- P/E Ratio
- TDF N/A
- TVRD N/A
- Revenue Growth
- TDF N/A
- TVRD N/A
- 52 Week Low
- TDF $7.15
- TVRD $8.13
- 52 Week High
- TDF $10.62
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- TDF 65.16
- TVRD 58.98
- Support Level
- TDF $10.55
- TVRD $22.91
- Resistance Level
- TDF $10.70
- TVRD $27.25
- Average True Range (ATR)
- TDF 0.13
- TVRD 1.48
- MACD
- TDF 0.02
- TVRD 0.30
- Stochastic Oscillator
- TDF 96.61
- TVRD 97.11
About TDF Templeton Dragon Fund Inc.
Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invests in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.